MENU
OLMA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Olema Oncology (OLMA) Earnings Date & Reports

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company... Show more

A.I. Advisor
published Earnings

OLMA is expected to report earnings to fall 8.96% to -66 cents per share on March 23

Olema Oncology OLMA Stock Earnings Reports
Q4'26
Est.
$-0.66
Q3'26
Missed
by $0.13
Q2'26
Missed
by $0.06
Q1'26
Beat
by $0.01
Q4'25
Beat
by $0.02
The last earnings report on November 10 showed earnings per share of -73 cents, missing the estimate of -60 cents. With 853.22K shares outstanding, the current market capitalization sits at 641.36M.
A.I.Advisor
Nov 09, 2026

Olema Pharmaceuticals (OLMA) Earnings Preview: All Eyes on Palazestrant Trial Progress as Losses Deepen

Key Takeaways

  • Olema Pharmaceuticals (OLMA) is set to report third-quarter 2026 results for the period ended September 30, 2026, on or around November 9–10, 2026.
  • Wall Street expects a wider net loss of roughly $0.64 per share, compared with a $0.49 loss in the prior-year quarter, as late-stage trial spending accelerates.
  • As a clinical-stage biotech, Olema remains effectively pre-revenue, so investors will watch pipeline updates more closely than the income statement.
  • Attention is focused on the OPERA-01 and OPERA-02 Phase 3 trials of palazestrant and early data for OP-3136, a KAT6 inhibitor.
  • The prior quarter (Q2 2026) missed estimates with a $0.61 loss, adding a cautious tone heading into this report.
  • For more context, visit our pages for Major News, Today's Price Move, Price Targets, and Forecast on Olema Pharmaceuticals.
  • You can also explore Trending AI Robots to discover AI-driven trading strategies across the market.

Earnings Context and Why It Matters

Olema Pharmaceuticals, also known as Olema Oncology, is a clinical-stage biopharmaceutical company developing therapies for women's cancers. Its lead candidate, palazestrant, is a complete estrogen receptor (ER) antagonist in two pivotal Phase 3 trials for ER-positive, HER2-negative metastatic breast cancer. Because the company generates essentially no product revenue, quarterly earnings serve primarily as a checkpoint on spending and cash runway, while the real value driver is clinical progress. With the OPERA-01 monotherapy readout expected in the first quarter of 2027, each report is scrutinized for signs of trial momentum, enrollment trends, and any shifts in timelines that could reshape the investment thesis.

Earnings Expectations

Consensus estimates point to a net loss of approximately $0.64 per share for the third quarter of 2026, according to data from MarketWatch and FactSet, though some aggregators cluster near $0.60. That compares with a $0.49 loss in the same quarter a year ago, when Olema reported a net loss of $42.2 million and ended the period with $329.0 million in cash and marketable securities. Revenue expectations are negligible, reflecting the company's pre-commercial status. The widening expected loss largely reflects higher research and development (R&D) spending tied to the OPERA-01 and OPERA-02 late-stage trials and the advancement of OP-3136. In Q2 2026, Olema posted a $0.61 loss, missing the roughly $0.55 consensus, with R&D expenses climbing to $57.8 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Olema Pharmaceuticals alongside the broader biotechnology space, the AI Screener offers a streamlined way to surface relevant opportunities and monitor shifting technical conditions.

Market Reaction and Investor Sentiment

Sentiment heading into this report is cautious but not bearish. Olema shares have been volatile in recent months, and the stock's reaction is likely to hinge less on the loss figure itself and more on any commentary around trial timelines, data-readout schedules, and cash runway. The Q2 2026 miss underscores how operating-expense growth can outpace estimates as pivotal studies accelerate. Analysts maintain an average "Buy" rating with a target price well above current trading levels, but the wide gap between estimates on the loss per share reflects uncertainty about the pace of spending. Key risks include potential delays in the OPERA-01 readout, competitive developments in the oral selective estrogen receptor degrader (SERD) market, and any signal that the company may need additional financing before a pivotal data catalyst.

Forward Outlook and Key Factors to Monitor

The most important catalyst on the horizon remains the OPERA-01 Phase 3 readout for palazestrant monotherapy, now expected in the first quarter of 2027. Management commentary on enrollment completion, data maturation, and any interaction with regulators will carry more weight than the quarterly loss figure.

Investors should also monitor the OPERA-02 frontline combination trial, which pairs palazestrant with ribociclib, as well as early safety and efficacy signals for OP-3136, a KAT6 (lysine acetyltransferase 6) inhibitor in Phase 1 development. Combination data expected in the first half of next year could further shape the pipeline narrative.

On the financial side, watch R&D expense trends and the company's cash position, which is widely viewed as sufficient to fund operations through the next major data catalyst. Any indication of accelerated spending or a shift in the expected data timeline would be closely scrutinized. As with most clinical-stage oncology names, the investment case hinges on binary trial outcomes rather than near-term profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations